Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Regulatory / EU Revokes TAVNEOS Marketing Authorization
Regulatory marketing authorization revocation

EU Revokes TAVNEOS Marketing Authorization

Analysis based on 11 articles · First reported Jun 26, 2026 · Last updated Jun 26, 2026

Sentiment
-60
Attention
4
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The revocation of TAVNEOS's marketing authorization in the European Union will negatively impact CSL Limited and Fresenius Medical Care, who commercialize the drug, potentially leading to a decrease in their revenue from this product. Amgen, which acquired ChemoCentryx (the developer of TAVNEOS), may also experience an indirect negative impact.

pharmaceuticals biotechnology
Event Summary

The European Union — European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the revocation of the European Union marketing authorization for TAVNEOS (avacopan), a treatment for ANCA-associated vasculitis. This recommendation stems from concerns regarding data handling in the pivotal Phase 3 ADVOCATE trial. The International — European Commission is expected to make a final decision soon. If confirmed, TAVNEOS will no longer be authorized in the EU, impacting its commercialization partners CSL Limited and Fresenius Medical Care, and indirectly Amgen, which acquired ChemoCentryx, the drug's developer.

Entities Involved
stock
CSL Limited
CSL Limited is a commercialization partner for TAVNEOS outside the US and will be significantly impacted by the revocation of its marketing authorization in the EU.
Importance 90.0 Sentiment -70.0
stock
Fresenius Medical Care
Fresenius Medical Care, a joint company with Fresenius_Medical_Care, is a commercialization partner for TAVNEOS and will be directly affected by the revocation of its marketing authorization in the EU.
Importance 90.0 Sentiment -70.0
govactor
European Union — European Medicines Agency
The European Union — European Medicines Agency's CHMP recommended the revocation of the marketing authorization for TAVNEOS, impacting its availability in the EU.
Importance 80.0 Sentiment -20.0
govactor
International — European Commission
The International — European Commission is expected to make a final decision on the CHMP's recommendation, which will determine the future of TAVNEOS in the EU.
Importance 70.0 Sentiment -20.0
stock
ChemoCentryx
ChemoCentryx developed TAVNEOS and is the NDA holder in the US. Although acquired by Amgen, the revocation of the EU marketing authorization for its developed drug is a negative development.
Importance 60.0 Sentiment -50.0
alliance
European Union
The European Union is the region where the marketing authorization for TAVNEOS is being revoked, affecting patients and pharmaceutical companies operating within its borders.
Importance 60.0 Sentiment 0.0
stock
Amgen
Amgen acquired ChemoCentryx in 2022, and as such, the revocation of the EU marketing authorization for TAVNEOS, a drug developed by ChemoCentryx, will have an indirect negative impact on Amgen.
Importance 50.0 Sentiment -30.0
Relationships
European Union — European Medicines Agency related ↔ International — European Commission
European Union — European Medicines Agency related ↔ European Union
International — European Commission related ↔ European Union
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.